EN DE

Corentec Co (104540) Fair Value & Analysis

Healthcare · KR · Market cap 51.1B KRW

CC Corentec Co 104540 · KQ
Price4,290 KRW
Fair Value10,770 KRW
Upside+151.1%
Quality66/100
Watch Corentec Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 4.5% net margin
Low debt · generates free cash flow
Ranks above peers (8/9)
Narrow moat 35/100
Evidence: Medium Range 8,078 KRW – 13,463 KRW Share as image

Fair value as of: Jul 22, 2026

From 24 valuation models · updated 19 days ago

Share price +4.5% over the past month.

A solid business, screening 151% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (8,078 KRW). The market is more pessimistic than our downside scenario.
  • Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

21,600 KRW 3,720 KRW Fair Value 10,770 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 3,720 KRW – 21,600 KRW · fair‑value band 8,078 KRW – 13,463 KRW · the 4,290 KRW price screens below the 10,770 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Corentec Co (104540) currently trades at 4,290 KRW, while our model-based Fair Value estimate is 10,770 KRW, implying the stock looks roughly 151.1% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Corentec Co generated revenue of 102B KRW at a net margin of 4.5%. Revenue grew 8.6% year over year. It earns a return on equity of 4.2%. Net debt stands at 11.1B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 8,078 KRW (bear case) to 13,463 KRW (bull case); at 4,290 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 151%, 104540 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 23,931 KRW 41,104 KRW 70,201 KRW 80
Residual Income 5,103 KRW 5,471 KRW 6,234 KRW 76
Rev-Margin DCF 12,877 KRW 19,103 KRW 27,194 KRW 74
All 24 models by family
DCF Models
FCF DCF 24,101 KRW 42,802 KRW 75,348 KRW 38
Owner Earnings 9,199 KRW 15,816 KRW 27,332 KRW 31
5Y Revenue Exit 12,877 KRW 18,980 KRW 26,794 KRW 39
5Y EBITDA Exit 16,011 KRW 25,443 KRW 36,972 KRW 41
5Y P/E Exit 13,494 KRW 20,254 KRW 27,705 KRW 38
10Y Revenue Exit 16,240 KRW 23,301 KRW 33,298 KRW 36
10Y EBITDA Exit 18,545 KRW 28,037 KRW 41,820 KRW 37
10Y P/E Exit 16,876 KRW 24,235 KRW 34,060 KRW 35
Earnings-Based
Graham-Dodd 3,329 KRW 15,452 KRW 21,225 KRW 54
Lynch FV 4,075 KRW 5,821 KRW 7,567 KRW 50
PEG = 1.0 4,075 KRW 5,821 KRW 7,567 KRW 46
EPV 7,274 KRW 8,313 KRW 9,222 KRW 59
Multiples
P/E Multiple 8,078 KRW 10,770 KRW 13,463 KRW 63
P/S Multiple 6,242 KRW 8,323 KRW 10,403 KRW 58
P/B Multiple 6,242 KRW 8,323 KRW 10,403 KRW 55
EV/EBIT 10,313 KRW 13,405 KRW 16,496 KRW 53
EV/EBITDA 13,131 KRW 17,162 KRW 21,193 KRW 54
EV/Revenue 7,658 KRW 10,495 KRW 13,332 KRW 43
Asset-Based
NCAV (Graham) 3,064 KRW 4,106 KRW 6,128 KRW 50
Growth DCF
Growth DCF 23,931 KRW 41,104 KRW 70,201 KRW 80
Rev-Margin DCF 12,877 KRW 19,103 KRW 27,194 KRW 74
Economic Profit
Residual Income 5,103 KRW 5,471 KRW 6,234 KRW 76
ROIC Compounder 7,793 KRW 10,282 KRW 13,677 KRW 72
Growth Earnings
Growth-Adj P/E 6,667 KRW 9,524 KRW 12,381 KRW 68

Widest divergence: DCF Models (23,301 KRW) versus Asset-Based (4,106 KRW). Highest evidence: Growth DCF (80).

Notify me when 104540 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 102B KRW
Revenue growth (YoY) +8.6%
Net margin 4.5%
Return on equity 4.2%
Free cash flow 22.9B KRW FY2025
Operating margin 3.6%
More key figures
EPS growth (YoY) -56.8%
Net debt 11.1B KRW FY2025

Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 65 · Market factors (momentum, volatility) 24

Profitability 40
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 92
Earnings quality: real cash, not paper profit
Fin. Strength 44
Balance sheet, leverage, solvency risk
Investment 87
Disciplined investing over empire-building
Low Volatility 63
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 76
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Corentec Co., Ltd., develops and sells orthopedic artificial joints in South Korea. Its orthopedic products include hip systems, such as Bencox ID stems, Bencox stems, Bencox modular revision stems, Bencox m stems, and Benfix long stems; and Bencox cups, Bencox bipolar cups, Bencox mirabo cups, and Bencox mirabo multi-hole cups.

Full company description

Corentec Co., Ltd., develops and sells orthopedic artificial joints in South Korea. Its orthopedic products include hip systems, such as Bencox ID stems, Bencox stems, Bencox modular revision stems, Bencox m stems, and Benfix long stems; and Bencox cups, Bencox bipolar cups, Bencox mirabo cups, and Bencox mirabo multi-hole cups. The company also offers Lospa and Exult knee systems; spine systems, such as Lospa IS systems; Coralis shoulder systems; and trauma systems, including LCfit HTO plate systems and Optirad volar plate system. Corentec Co., Ltd. was founded in 2000 and is headquartered in Cheonan-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Corentec Co reported revenue of 100B KRW in FY2025 versus 44.6B KRW in FY2021, a compound +22.5%/yr. Reported net income was 6.3B KRW in FY2025, compounding +69.2%/yr from FY2021.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
100B KRW
Latest YoY
+7.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.9%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.9%
Revenue +22.5%/yr
FY21 44.6B KRW
FY22 63.9B KRW
FY23 92.0B KRW
FY24 93.7B KRW
FY25 100B KRW
Net income +69.2%/yr
FY21 764M KRW
FY22 1.8B KRW
FY23 4.1B KRW
FY24 −2.6B KRW
FY25 6.3B KRW

Watch 104540: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Corentec Co Fair Value". https://www.fairvalue-calculator.com/stock/104540

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +151% · Top 25%
Return on equity (TTM) 4% · Above median
Return on assets 3% · Above median
Net margin (TTM) 5% · Above median
Operating margin (TTM) 4% · Below median
Revenue growth 9% · Above median
Debt / equity 0.06× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 43 · sector 29
PAST 17 · sector 8
HEALTH 97 · sector 97
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
DexCom, Inc DXCM $74.96 $38.95 -48%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%

Compare Corentec Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Corentec Co (104540) overvalued or undervalued?
As of Jul 22, 2026, our model estimates a fair value of 10,770 KRW versus a price of 4,290 KRW, about +151% (undervalued).
What is the fair value of 104540?
Our model-based fair value for Corentec Co is 10,770 KRW (as of Jul 22, 2026), built from audited fundamentals. The current price is 4,290 KRW.
What is the quality score of 104540?
Corentec Co has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Corentec Co (104540)?
Corentec Co reported trailing-twelve-month revenue of about 102B KRW (latest available figure, as of Jul 22, 2026).
What is the net profit margin of 104540?
The net profit margin of Corentec Co is about 4.5%, meaning it keeps roughly 4.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Corentec Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.